ARTICLE | Top Story

ChemoCentryx rebounds on updated diabetic nephropathy data

December 13, 2014 2:31 AM UTC

ChemoCentryx Inc. (NASDAQ:CCXI) jumped $1.11 (25%) to $5.60 on Friday after reporting that CCX140 plus standard of care met the primary endpoint of reducing the urine albumin-to-creatinine ratio (UACR) over 52 weeks vs. placebo plus SOC in a Phase II trial to treat diabetic nephropathy. SOC consisted of stable doses of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB).

At 52 weeks, UACR was reduced by 20% for patients receiving 5 mg CCV140 vs. 3% for placebo patients (p=0.0148). The company previously said a 20% reduction would be considered a success. ChemoCentryx shares fell $2.01 to $6.25 on Sept. 10, 2013, when the company reported the CCR2 inhibitor did not meet that benchmark at a 12-week interim analysis (see BioCentury Extra, Sept. 10, 2013). ...